

## ACC-1 β-Lactamase- producing *Salmonella* *enterica* Serovar Typhi, India

**To the Editor:** Typhoid fever, caused by *Salmonella enterica* serovar Typhi, is a serious form of enteric fever. In 2000, the worldwide number of typhoid cases was estimated to be >21,000,000, and there were >200,000 deaths from this disease (1).

Ciprofloxacin is the first-line drug of choice for treatment of patients with typhoid fever, but there has been an increase in strains resistant to ciprofloxacin (2) and resistance to third-generation cephalosporins has emerged (3). There are sporadic reports of high resistance to ceftriaxone in typhoidal salmonellae (3,4) in which CTX-M-15 and SHV-12 extended spectrum β-lactamases (ESBLs) have been reported. To date, there are no reports of *AmpC* β-lactamases in typhoidal salmonellae. *AmpC* β-lactamases confer resistance to a broad spectrum of β-lactams, which greatly limits therapeutic options. We investigated an isolate of *S. Typhi* by using serotyping, antimicrobial drug susceptibility testing, PCR screening for β-lactamase genes, and sequence analysis to confirm the identity of the isolate and the β-lactamase gene involved in conferring resistance to this isolate.

The isolate was obtained in Bangalore, India, in August 2009, from the blood of a female patient (14 years of age) who was hospitalized because of signs and symptoms of enteric fever. She had no history of having received antimicrobial drugs. After a blood sample was cultured, the patient was empirically treated with ceftriaxone but did not clinically improve.

Culture yielded gram-negative bacteria after 48 hours. The isolate was identified by standard biochemi-

cal methods as *S. Typhi*. Identification was confirmed by using *Salmonella* spp. polyvalent O, O9, and H:d antisera (Murex Biotech, Dartford, UK). Susceptibility to antimicrobial drugs was assessed by using the Kirby-Bauer disk diffusion method according to Clinical and Laboratory Standards Institute guidelines ([www.clsi.org](http://www.clsi.org)). The isolate was resistant to ampicillin, piperacillin, cefoxitin, cefotaxime, ceftazidime, ceftriaxone, aztreonam, amoxicillin/clavulanate, and cefepime. It was susceptible to chloramphenicol, trimethoprim/sulfamethoxazole, nalidixic acid, ciprofloxacin, and meropenem.

Treatment was changed to ciprofloxacin (500 mg every 12 h for 7 d). The patient recovered within 72 hours and was discharged. MICs were determined for ciprofloxacin, gatifloxacin, ofloxacin, ceftazidime, ceftriaxone, and amoxicillin/clavulanate by using the Etest (AB Biodisk, Solna, Sweden) (Table). MIC for ceftriaxone was confirmed by an agar dilution method ([www.clsi.org](http://www.clsi.org)). The isolate was tested for ESBLs by using a method with disks containing ceftazidime (30 μg) and ceftazidime/clavulanate (30 μg/10 μg). The *AmpC* disk test for detection of plasmid-mediated *AmpC* β-lactamase was conducted according to standard methods (5).

PCR screening and sequencing was performed to identify β-lactamase resistance genes *bla*<sub>TEM</sub>, *bla*<sub>SHV</sub>, *bla*<sub>OXA-1</sub> group, *bla*<sub>CTX-M</sub>, and *AmpC* as described (6,7). Sequencing of β-lactamase gene amplicons was conducted at the Vector Control Research Centre in Pondicherry, India. The BLASTN program ([www.ncbi.nlm.nih.gov/BLAST](http://www.ncbi.nlm.nih.gov/BLAST)) was used for database searching. We also

used a nested PCR specific for the flagellin gene of *S. Typhi* to confirm identity of the isolate (8). The nested PCR amplicon was sequenced to confirm identity of the flagellin (*fliC*) gene of *S. Typhi*. Sequencing of the flagellin gene product was conducted by Cistron Bioscience (Chennai, India).

The isolate was negative for ESBL production. PCR amplification and sequencing showed that the isolate harbored *bla*<sub>TEM-1</sub> and *bla*<sub>ACC-1</sub>. The isolate was negative by PCR for other β-lactamases tested. TEM-1 is one of the most commonly encountered β-lactamases in the family *Enterobacteriaceae* and can hydrolyze narrow-spectrum penicillins and cephalosporins.

We report ACC-1 *AmpC* β-lactamase in typhoidal salmonellae. *S. Typhi* could have acquired the *AmpC* β-lactamase from drug-resistant bowel flora. After the isolate was found to be highly resistant to ceftriaxone, the change in therapy to ciprofloxacin helped in recovery of the patient without any sequelae.

ACC-1 *AmpC* β-lactamases originated in *Hafnia alvei* and are now found in various members of the family *Enterobacteriaceae* (9). The ACC-1 *AmpC* β-lactamases are exceptional in that they do not confer resistance to cephamycins (10). Our isolate contained *bla*<sub>TEM-1</sub> and *bla*<sub>ACC-1</sub> and was resistant to cefoxitin and cefepime but susceptible to meropenem. Bidet et al. (9) reported isolating *Klebsiella pneumoniae* resistant to cefoxitin and cefepime and intermediate resistance to imipenem. Atypical resistance was attributed to ACC-1 β-lactamase production and loss of a 36-kDa major outer membrane protein (9). We did

Table. MICs for isolate of *Salmonella enterica* serovar Typhi, Bangalore, India, 2009

Drug	MIC
Amoxicillin/clavulanic acid	>256
Piperacillin/tazobactam	12
Ceftazidime	>256
Cefotaxime	>256
Ceftriaxone	>256
Ciprofloxacin	0.094

not analyze changes in the outer membrane proteins responsible for alteration of permeability.

Continual monitoring of drug resistance patterns is imperative. Antimicrobial drug susceptibility testing should be conducted for clinical isolates, and empirical antimicrobial drug therapy should be changed accordingly. *AmpC*  $\beta$ -lactamase genes will eventually be transferred to typhoidal salmonellae, which may pose a threat to public health. Spread of broad-spectrum  $\beta$ -lactamases would greatly limit therapeutic options and leave only carbapenems and tetracycline as secondary antimicrobial drugs.

**Bindiganavile N. Gokul,  
Godfred A. Menezes,  
and Belgode N. Harish**

Author affiliations: Sri Devaraj Urs Medical College, Kolar, India (B.N. Gokul, G.A. Menezes); Fortis Hospitals, Bangalore, India (B.N. Gokul); and Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry, India (G.A. Menezes, B.N. Harish)

DOI: 10.3201/eid1607.091643

#### References

1. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. *Bull World Health Organ.* 2004;82:346–53.
2. Harish BN, Menezes GA, Sarangapani K, Parija SC. A case report and review of the literature: ciprofloxacin resistant *Salmonella enterica* serovar Typhi in India. *J Infect Dev Ctries.* 2008;2:324–7. DOI: 10.3855/jidc.229
3. Al Naiemi N, Zwart B, Rijnsburger MC, Roosendaal R, Debets-Ossenkopp YJ, Mulder JA, et al. Extended-spectrum-beta-lactamase production in a *Salmonella enterica* serotype Typhi strain from the Philippines. *J Clin Microbiol.* 2008;46:2794–5. DOI: 10.1128/JCM.00676-08
4. Rotimi VO, Jamal W, Pal T, Sovenned A, Albert MJ. Emergence of CTX-M-15 type extended-spectrum  $\beta$ -lactamase-producing *Salmonella* spp. in Kuwait and the United Arab Emirates. *J Med Microbiol.* 2008;57:881–6. DOI: 10.1099/jmm.0.47509-0
5. Singhal S, Mathur T, Khan S, Upadhyay DJ, Chugh S, Gaiind R, et al. Evaluation of methods for *AmpC* beta-lactamase in gram negative clinical isolates from tertiary care hospitals. *Indian J Med Microbiol.* 2005;23:120–4. DOI: 10.4103/0255-0857.16053
6. Mabilat C, Goussard S. PCR detection and identification of genes for extended spectrum  $\beta$ -lactamases. In: Persiang DH, Smith TF, Tenover FC, White TJ, editors. *Diagnostic molecular microbiology: principles and applications.* Washington: American Society for Microbiology; 1993. p. 553–9.
7. Pérez-Pérez FJ, Hanson ND. Detection of plasmid-mediated *AmpC*  $\beta$ -lactamase genes in clinical isolates by using multiplex PCR. *J Clin Microbiol.* 2002;40:2153–62. DOI: 10.1128/JCM.40.6.2153-2162.2002
8. Frankel G, Newton SM, Schoolnik GK, Stocker BA. Unique sequences in region VI of the flagellin gene of *Salmonella typhi*. *Mol Microbiol.* 1989;3:1379–83. DOI: 10.1111/j.1365-2958.1989.tb00119.x
9. Bidet P, Burghoffer B, Gautier V, Brahimi N, Mariani-Kurkdjian P, El-Ghoneimi A, et al. In vivo transfer of plasmid-encoded ACC-1 *ampC* from *Klebsiella pneumoniae* to *Escherichia coli* in an infant and selection of impermeability to imipenem in *K. pneumoniae*. *Antimicrob Agents Chemother.* 2005;49:3562–5. DOI: 10.1128/AAC.49.8.3562-3565.2005
10. Bauernfeind A, Schneider I, Jungwirth R, Sahly H, Ullmann U. A novel type of *AmpC*  $\beta$ -lactamase, ACC-1, produced by a *Klebsiella pneumoniae* strain causing nosocomial pneumonia. *Antimicrob Agents Chemother.* 1999;43:1924–31.

Address for correspondence: Belgode N. Harish, Department of Microbiology, Jawaharlal Institute of Postgraduate Medical Education and Research, Pondicherry 605006, India; email: drbnharish@yahoo.com



## Endocarditis Caused by *Actinobaculum schaalii*, Austria

**To the Editor:** In May 2009, a 52-year-old man was hospitalized with middle cerebral artery stroke and fever of unknown origin. He had a complicated medical history of middle cerebral artery stroke and mechanical valve replacement of the aortic valve 2 years earlier and gastric-duodenal angiodysplasia. Two months before the most recent hospitalization, he had been hospitalized because of fever and anemia; blood cultures were positive; Gram stain identified coryneform rods that did not grow in culture. Antimicrobial drug therapy with levofloxacin (400 mg 1 $\times$ /d) was initiated, and the patient was discharged.

At the most recent admission, laboratory testing showed a leukocyte count of  $5.92 \times 10^3$  cells/ $\mu$ L, with 81% neutrophils, 7% lymphocytes, and 9% monocytes; thrombocyte count was  $338 \times 10^3$  cells/ $\mu$ L. C-reactive protein level was 62.6 mg/L (reference value <8 mg/L). Basic serum and urine chemical profiles and urine culture were unremarkable. Empiric antimicrobial drug therapy with piperacillin-tazobactam (4.5 g 3 $\times$ /d) was initiated and discontinued after 5 days because of clinical improvement. The next day, the patient's condition deteriorated, C-reactive protein level increased from 15 mg/L to 32 mg/L, and blood was collected for culture on the day after piperacillin-tazobactam discontinuation and the next 2 days. After 4 days of incubation, bacterial growth was detected in 1 aerobic and 3 anaerobic samples. Gram stain showed positive coryneform rods. Within 48–72 hours, the isolate yielded growth on blood, chocolate, and Schaedler agar; colonies were 1–2 mm in diameter and gray. The specificity of the organism was unsatisfactory with the system we used (API Coryne sys-